Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

Tromsø, Norway, 7 February 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio.

T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.

This launch represents the Company’s first non-novel enzyme in its expanding portfolio and fulfils customer requests for such enzymes. The high-quality and commercial grade ligase is produced under the strict ISO 13485 guidelines. It fits synergistically in the Company’s portfolio and can be used by customers either in combination with their own enzymes or alongside ArcticZymes novel enzymes.

ArcticZymes has several other ligase products in development. Numerous prototypes of novel ligases are currently with leading commercial customers for early access evaluations. Customer feedback from these evaluations will then steer the Company’s plans to commercialise further ligases in 2019.

Jethro Holter, Managing Director ArcticZymes said:

“The launch of the T4 DNA ligase fits with our strategy to expand our current portfolio beyond novel enzyme products. Our goal is to continue to leverage our experience to grow a synergistic portfolio through organic and non-organic growth initiatives.

“As a trusted component supplier to the industry we are transitioning the business towards becoming the leading one-stop shop for molecular biology enzymes.